Monoclonal Antibodies: Meeting the Challenges in Manufacturing, Formulation, Delivery and Stability of Final Drug Product

0 avg rating
( 0 ratings by Goodreads )
 
9780081002964: Monoclonal Antibodies: Meeting the Challenges in Manufacturing, Formulation, Delivery and Stability of Final Drug Product

Monoclonal antibodies (MAbs) are currently the major class of protein bio therapeutic being developed by biotechnology and pharmaceutical companies. Monoclonal Antibodies discusses the challenges and issues revolving around development of a monoclonal antibody produced by recombinant DNA technology into a therapeutic agent.This book covers downstream processing which includes design of processes to manufacture the formulation, formulation design, fill and finish into closure systems and routes of administration. The characterization of the final drug product is covered where the use of biophysical methods combined with genetic engineering is used to understand the solution properties of the formulation. The latter has become very important since many indications such as arthritis and asthma require the development of formulations for subcutaneous delivery (SC). The development of formulations for IV delivery is also important and comes with a different set of challenges. The challenges and strategies that can overcome these limitations are discussed in this book, starting with an introduction to these issues, followed by chapters detailing strategies to deal with them. Subsequent chapters explore the processing and storage of mAbs, development of delivery device technologies and conclude with a chapter on the future of mAbs in therapeutic remedies.



  • Discusses the challenges to develop MAbs for intravenous (IV) and subcutaneous delivery (SC)
  • Presents strategies to meet the challenges in development of MAbs for SC and IV administration
  • Discusses the use of biophysical analytical tools coupled with MAb engineering to understand what governs MAb properties at high concentration

"synopsis" may belong to another edition of this title.

Product Description:

Monoclonal Antibodies

About the Author:

Steven J. Shire is currently consulting and serving as an adjunct faculty member of the USC School of Pharmacy and University of Connecticut School of Pharmaceutical Sciences. He was at Genentech for 32 years where the majority of his career was in the pharmaceutical development department. He retired in June 2013 as Staff Scientist in the Late Stage Pharmaceutical Development Department. He has been responsible for directing research and development of formulations for a variety of recombinant human proteins including Pulmozyme® and Xolair®. Dr. Shire has served as the chair of the American Association of Pharmaceutical Scientists (AAPS) Biotechnology Section, and was elected as a Fellow of AAPS in 1998 and member at large to the AAPS Executive Council in 2001. He has published over 80 reviews and papers dealing with various aspects of formulation and pharmaceutical development of therapeutic proteins.

"About this title" may belong to another edition of this title.

Top Search Results from the AbeBooks Marketplace

1.

Steven Shire
Published by Woodhead Publishing Ltd 2015-04-30 (2015)
ISBN 10: 0081002963 ISBN 13: 9780081002964
New Hardcover Quantity Available: 5
Seller
Chiron Media
(Wallingford, United Kingdom)
Rating
[?]

Book Description Woodhead Publishing Ltd 2015-04-30, 2015. Hardcover. Book Condition: New. Bookseller Inventory # NU-ELS-00000896

More Information About This Seller | Ask Bookseller a Question

Buy New
£ 93.75
Convert Currency

Add to Basket

Shipping: £ 2.99
From United Kingdom to U.S.A.
Destination, Rates & Speeds

2.

Steven Shire
Published by ELSEVIER SCIENCE TECHNOLOGY, United Kingdom (2015)
ISBN 10: 0081002963 ISBN 13: 9780081002964
New Hardcover Quantity Available: 1
Seller
The Book Depository
(London, United Kingdom)
Rating
[?]

Book Description ELSEVIER SCIENCE TECHNOLOGY, United Kingdom, 2015. Hardback. Book Condition: New. 232 x 156 mm. Language: English . Brand New Book. Monoclonal antibodies (MAbs) are currently the major class of protein bio therapeutic being developed by biotechnology and pharmaceutical companies. Monoclonal Antibodies discusses the challenges and issues revolving around development of a monoclonal antibody produced by recombinant DNA technology into a therapeutic agent.This book covers downstream processing which includes design of processes to manufacture the formulation, formulation design, fill and finish into closure systems and routes of administration. The characterization of the final drug product is covered where the use of biophysical methods combined with genetic engineering is used to understand the solution properties of the formulation. The latter has become very important since many indications such as arthritis and asthma require the development of formulations for subcutaneous delivery (SC). The development of formulations for IV delivery is also important and comes with a different set of challenges. The challenges and strategies that can overcome these limitations are discussed in this book, starting with an introduction to these issues, followed by chapters detailing strategies to deal with them.Subsequent chapters explore the processing and storage of mAbs, development of delivery device technologies and conclude with a chapter on the future of mAbs in therapeutic remedies. Bookseller Inventory # LIB9780081002964

More Information About This Seller | Ask Bookseller a Question

Buy New
£ 110.62
Convert Currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, Rates & Speeds

3.

Steven Shire
Published by ELSEVIER SCIENCE TECHNOLOGY, United Kingdom (2015)
ISBN 10: 0081002963 ISBN 13: 9780081002964
New Hardcover Quantity Available: 1
Seller
The Book Depository US
(London, United Kingdom)
Rating
[?]

Book Description ELSEVIER SCIENCE TECHNOLOGY, United Kingdom, 2015. Hardback. Book Condition: New. 232 x 156 mm. Language: English . Brand New Book. Monoclonal antibodies (MAbs) are currently the major class of protein bio therapeutic being developed by biotechnology and pharmaceutical companies. Monoclonal Antibodies discusses the challenges and issues revolving around development of a monoclonal antibody produced by recombinant DNA technology into a therapeutic agent.This book covers downstream processing which includes design of processes to manufacture the formulation, formulation design, fill and finish into closure systems and routes of administration. The characterization of the final drug product is covered where the use of biophysical methods combined with genetic engineering is used to understand the solution properties of the formulation. The latter has become very important since many indications such as arthritis and asthma require the development of formulations for subcutaneous delivery (SC). The development of formulations for IV delivery is also important and comes with a different set of challenges. The challenges and strategies that can overcome these limitations are discussed in this book, starting with an introduction to these issues, followed by chapters detailing strategies to deal with them.Subsequent chapters explore the processing and storage of mAbs, development of delivery device technologies and conclude with a chapter on the future of mAbs in therapeutic remedies. Bookseller Inventory # LIB9780081002964

More Information About This Seller | Ask Bookseller a Question

Buy New
£ 115.45
Convert Currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, Rates & Speeds

4.

SHIRE , STEVEN
Published by Woodhead Publishing (2015)
ISBN 10: 0081002963 ISBN 13: 9780081002964
New Hardcover Quantity Available: 1
Seller
Herb Tandree Philosophy Books
(Stroud, GLOS, United Kingdom)
Rating
[?]

Book Description Woodhead Publishing, 2015. Hardback. Book Condition: NEW. 9780081002964 This listing is a new book, a title currently in-print which we order directly and immediately from the publisher. Bookseller Inventory # HTANDREE0890025

More Information About This Seller | Ask Bookseller a Question

Buy New
£ 137.50
Convert Currency

Add to Basket

Shipping: £ 8
From United Kingdom to U.S.A.
Destination, Rates & Speeds

5.

SHIRE , STEVEN
Published by Woodhead Publishing (2015)
ISBN 10: 0081002963 ISBN 13: 9780081002964
New Hardcover Quantity Available: 1
Seller
Herb Tandree Philosophy Books
(Stroud, GLOS, United Kingdom)
Rating
[?]

Book Description Woodhead Publishing, 2015. Hardback. Book Condition: NEW. 9780081002964 This listing is a new book, a title currently in-print which we order directly and immediately from the publisher. Bookseller Inventory # HTANDREE01194007

More Information About This Seller | Ask Bookseller a Question

Buy New
£ 137.50
Convert Currency

Add to Basket

Shipping: £ 8
From United Kingdom to U.S.A.
Destination, Rates & Speeds

6.

Steven Shire
Published by Woodhead Publishing (2015)
ISBN 10: 0081002963 ISBN 13: 9780081002964
New Hardcover Quantity Available: 1
Seller
Rating
[?]

Book Description Woodhead Publishing, 2015. Book Condition: New. Bookseller Inventory # L9780081002964

More Information About This Seller | Ask Bookseller a Question

Buy New
£ 145.73
Convert Currency

Add to Basket

Shipping: £ 3.92
From Germany to U.S.A.
Destination, Rates & Speeds

7.

Steven Shire
Published by Oxford Elsevier LTD Apr 2015 (2015)
ISBN 10: 0081002963 ISBN 13: 9780081002964
New Quantity Available: 1
Rating
[?]

Book Description Oxford Elsevier LTD Apr 2015, 2015. Buch. Book Condition: Neu. 238x154x17 mm. Neuware - Monoclonal antibodies (MAbs) are currently the major class of protein bio therapeutic being developed by biotechnology and pharmaceutical companies. Monoclonal Antibodies discusses the challenges and issues revolving around development of a monoclonal antibody produced by recombinant DNA technology into a therapeutic agent.This book covers downstream processing which includes design of processes to manufacture the formulation, formulation design, fill and finish into closure systems and routes of administration. The characterization of the final drug product is covered where the use of biophysical methods combined with genetic engineering is used to understand the solution properties of the formulation. The latter has become very important since many indications such as arthritis and asthma require the development of formulations for subcutaneous delivery (SC). The development of formulations for IV delivery is also important and comes with a different set of challenges. The challenges and strategies that can overcome these limitations are discussed in this book, starting with an introduction to these issues, followed by chapters detailing strategies to deal with them. Subsequent chapters explore the processing and storage of mAbs, development of delivery device technologies and conclude with a chapter on the future of mAbs in therapeutic remedies. 203 pp. Englisch. Bookseller Inventory # 9780081002964

More Information About This Seller | Ask Bookseller a Question

Buy New
£ 140.13
Convert Currency

Add to Basket

Shipping: £ 10.47
From Germany to U.S.A.
Destination, Rates & Speeds

8.

Steven Shire
Published by Oxford Elsevier LTD Apr 2015 (2015)
ISBN 10: 0081002963 ISBN 13: 9780081002964
New Quantity Available: 1
Seller
Rheinberg-Buch
(Bergisch Gladbach, Germany)
Rating
[?]

Book Description Oxford Elsevier LTD Apr 2015, 2015. Buch. Book Condition: Neu. 238x154x17 mm. Neuware - Monoclonal antibodies (MAbs) are currently the major class of protein bio therapeutic being developed by biotechnology and pharmaceutical companies. Monoclonal Antibodies discusses the challenges and issues revolving around development of a monoclonal antibody produced by recombinant DNA technology into a therapeutic agent.This book covers downstream processing which includes design of processes to manufacture the formulation, formulation design, fill and finish into closure systems and routes of administration. The characterization of the final drug product is covered where the use of biophysical methods combined with genetic engineering is used to understand the solution properties of the formulation. The latter has become very important since many indications such as arthritis and asthma require the development of formulations for subcutaneous delivery (SC). The development of formulations for IV delivery is also important and comes with a different set of challenges. The challenges and strategies that can overcome these limitations are discussed in this book, starting with an introduction to these issues, followed by chapters detailing strategies to deal with them. Subsequent chapters explore the processing and storage of mAbs, development of delivery device technologies and conclude with a chapter on the future of mAbs in therapeutic remedies. 203 pp. Englisch. Bookseller Inventory # 9780081002964

More Information About This Seller | Ask Bookseller a Question

Buy New
£ 140.13
Convert Currency

Add to Basket

Shipping: £ 14.94
From Germany to U.S.A.
Destination, Rates & Speeds

9.

Steven Shire
Published by Oxford Elsevier LTD Apr 2015 (2015)
ISBN 10: 0081002963 ISBN 13: 9780081002964
New Quantity Available: 1
Seller
Agrios-Buch
(Bergisch Gladbach, Germany)
Rating
[?]

Book Description Oxford Elsevier LTD Apr 2015, 2015. Buch. Book Condition: Neu. 238x154x17 mm. Neuware - Monoclonal antibodies (MAbs) are currently the major class of protein bio therapeutic being developed by biotechnology and pharmaceutical companies. Monoclonal Antibodies discusses the challenges and issues revolving around development of a monoclonal antibody produced by recombinant DNA technology into a therapeutic agent.This book covers downstream processing which includes design of processes to manufacture the formulation, formulation design, fill and finish into closure systems and routes of administration. The characterization of the final drug product is covered where the use of biophysical methods combined with genetic engineering is used to understand the solution properties of the formulation. The latter has become very important since many indications such as arthritis and asthma require the development of formulations for subcutaneous delivery (SC). The development of formulations for IV delivery is also important and comes with a different set of challenges. The challenges and strategies that can overcome these limitations are discussed in this book, starting with an introduction to these issues, followed by chapters detailing strategies to deal with them. Subsequent chapters explore the processing and storage of mAbs, development of delivery device technologies and conclude with a chapter on the future of mAbs in therapeutic remedies. 203 pp. Englisch. Bookseller Inventory # 9780081002964

More Information About This Seller | Ask Bookseller a Question

Buy New
£ 140.13
Convert Currency

Add to Basket

Shipping: £ 14.94
From Germany to U.S.A.
Destination, Rates & Speeds

10.

Steven Shire
Published by Oxford Elsevier LTD Apr 2015 (2015)
ISBN 10: 0081002963 ISBN 13: 9780081002964
New Quantity Available: 1
Seller
AHA-BUCH GmbH
(Einbeck, Germany)
Rating
[?]

Book Description Oxford Elsevier LTD Apr 2015, 2015. Buch. Book Condition: Neu. 238x154x17 mm. Neuware - Monoclonal antibodies (MAbs) are currently the major class of protein bio therapeutic being developed by biotechnology and pharmaceutical companies. Monoclonal Antibodies discusses the challenges and issues revolving around development of a monoclonal antibody produced by recombinant DNA technology into a therapeutic agent.This book covers downstream processing which includes design of processes to manufacture the formulation, formulation design, fill and finish into closure systems and routes of administration. The characterization of the final drug product is covered where the use of biophysical methods combined with genetic engineering is used to understand the solution properties of the formulation. The latter has become very important since many indications such as arthritis and asthma require the development of formulations for subcutaneous delivery (SC). The development of formulations for IV delivery is also important and comes with a different set of challenges. The challenges and strategies that can overcome these limitations are discussed in this book, starting with an introduction to these issues, followed by chapters detailing strategies to deal with them. Subsequent chapters explore the processing and storage of mAbs, development of delivery device technologies and conclude with a chapter on the future of mAbs in therapeutic remedies. 203 pp. Englisch. Bookseller Inventory # 9780081002964

More Information About This Seller | Ask Bookseller a Question

Buy New
£ 140.13
Convert Currency

Add to Basket

Shipping: £ 25.73
From Germany to U.S.A.
Destination, Rates & Speeds

There are more copies of this book

View all search results for this book